Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cough as a clinical manifestation of giant cell arteritis.

Scandinavian journal of rheumatology·2026
Same author

Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken.

Acta clinica Belgica·2023
Same author

Association between diagnostic outcomes and symptom pattern in fever and inflammation of unknown origin.

European journal of internal medicine·2023
Same author

Etiological spectrum and outcome of fever and inflammation of unknown origin. Does symptom duration matter?

European journal of internal medicine·2022
Same author

Rheumatic disorders among patients with fever of unknown origin: A systematic review and meta-analysis.

Seminars in arthritis and rheumatism·2022
Same author

Diagnosis of deficiency of adenosine deaminase type 2 in adulthood.

Scandinavian journal of rheumatology·2021

Related Experiment Video

Updated: Jun 7, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

The effect of plasmin on platelet function.

D Blockmans1, H Deckmyn, L Van den Hove

  • 1Department of General Internal Medicine, UZ, Gasthuisberg.

Platelets
|November 4, 2010
PubMed
Summary
This summary is machine-generated.

Plasmin

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 7, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Hematology
  • Biochemistry
  • Physiology

Background:

  • Controversy exists regarding plasmin's effects on human platelets.
  • Platelet function is crucial for hemostasis and thrombosis.
  • Understanding plasmin-platelet interactions is vital for thrombotic disorders.

Purpose of the Study:

  • To investigate the effects of plasmin on human platelet glycoproteins, aggregation, shape change, and secretion.
  • To elucidate the conditions under which plasmin modulates platelet activity.

Main Methods:

  • Utilized gel-filtered platelets (GFP) to control experimental conditions.
  • Assessed platelet responses (shape change, secretion, aggregation) to plasmin under varying conditions (presence/absence of fibrinogen, stirring, CaCl2).
  • Investigated plasmin's impact on platelet-bound fibrinogen and response to other agonists.

Main Results:

  • Plasmin's effects on platelets are observed in GFP, not platelet-rich plasma, due to alpha2-antiplasmin binding.
  • In the presence of fibrinogen, platelet function remains intact.
  • Stirring induces platelet shape change, secretion, and aggregation with plasmin, enhanced by CaCl2.
  • Without stirring, plasmin inhibits subsequent aggregation induced by other stimuli.

Conclusions:

  • Plasmin is a potent platelet-activating agent, inducing shape change and secretion.
  • Plasmin can induce platelet aggregation in stirred conditions, potentially by protecting bound fibrinogen.
  • Plasmin acts as a platelet inhibitor in unstirred conditions by degrading bound fibrinogen.